Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
HeartWare, Inc.
ClinicalTrials.gov Identifier:
NCT00751972
First received: September 10, 2008
Last updated: April 2, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to evaluate the safety and effectiveness of the HeartWare® LVAD System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death. The primary endpoint is survival at 180 days which is defined as alive on the originally implanted HeartWare® LVAD or transplanted or explanted for recovery. Patient must survive 60 days post-explant for recovery to be considered successful. Secondary endpoints include:

  • Overall survival
  • Incidence of all serious adverse events, neurocognitive status and unanticipated adverse device effects.
  • Incidence of all device failures and device malfunctions
  • Quality of Life improvement, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQoL EQ-5D
  • Functional status improvement, as measured by the New York Heart Association (NYHA) and 6-minute walk

The HeartWare® LVAD System was approved by the US FDA on November 20, 2012 as a bridge to cardiac transplantation (reference PMA P100047). Patients enrolled into this study will be followed to an outcome at six months, and then patients will receive continued follow-up in a separate study.


Condition Intervention
Chronic Heart Failure
Device: HeartWare® VAS

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure

Resource links provided by NLM:


Further study details as provided by HeartWare, Inc.:

Primary Outcome Measures:
  • The Primary Endpoint is Success at 180 Days Which is Defined as Alive on the Originally Implanted HeartWare® LVAD or Transplanted or Explanted for Recovery. Patient Must Survive 60 Days Post-explant for Recovery to be Considered Successful. [ Time Frame: 180 days ] [ Designated as safety issue: Yes ]
    The primary endpoint is success at 180 days which is defined as alive on the originally implanted HeartWare® LVAD or transplanted or explanted for recovery. A patient must survive 60 days post-explant for recovery to be considered successful.


Secondary Outcome Measures:
  • Survival to 180 Days [ Time Frame: 180 Days ] [ Designated as safety issue: Yes ]
    All subjects will be followed for date of death until 180 days.

  • Incidence of Adverse Events, Neurocognitive Status and Unanticipated Adverse Device Effects [ Time Frame: 180 Days ] [ Designated as safety issue: Yes ]
    Adverse events are only provided for patients who received a HeartWare Ventricular Assist Device (HeartWare® VAS). Adverse events as described by INTERMACS for the contemporaneous control population were not a part of the agreement for analysis and thus not provided by INTERMACS, and so not included in the Adverse Event Module and relevant Outcome Measures for comparison.

  • Incidence of All Device Failures and Device Malfunctions [ Time Frame: 180 Days ] [ Designated as safety issue: Yes ]
    The INTERMACS event device malfunction defined a failure of the HeartWare VAS as either pump failure or non-pump failure.

  • Quality of Life Change From Baseline to 180 Days, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Baseline and 180 Days ] [ Designated as safety issue: No ]

    KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life for patients with congestive heart failure. It is a predictive tool that tracks how patients are doing if they have weakened heart muscle due to prior heart attacks, heart valve problems, viral infections, or other causes.

    The KCCQ's questions are used to calculate scores in ten domains:

    Physical Limitation, Symptom Stability, Frequency, Burden and Total Symptom. Social Limitation, Self-Efficacy, Quality of Life, and Clinical Summary. Overall Summary: a combined measure of all the above

    For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.


  • Change in Distance Walked in the 6-minute Walk Test Between Baseline and 180 Days [ Time Frame: Baseline and 180 Days ] [ Designated as safety issue: No ]

    The 6MWT is a simple test which does not require expensive equipment or advanced training for technicians. The test involves asking the patient to walk the longest distance possible in a set interval of 6 min, through a walking course (corridor) preferably 30-m long. The patient can stop or slow down at any time and then resume walking, depending on his/her degree of fatigue.

    A longer distance walked is indicative of a better outcome.


  • Quality of Life Change From Baseline to 180 Days, as Measured by EuroQoL EQ-5D [ Time Frame: Baseline and 180 Days ] [ Designated as safety issue: No ]

    The EQ-5D is a standardized instrument for use as a generic measure of the quality of health-related life and of health outcome.

    The EuroQoL EQ-5D is a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

    Scores are transformed to a range of 0-100, in which higher scores reflect better health status.



Enrollment: 140
Study Start Date: August 2008
Study Completion Date: August 2013
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HeartWare® VAS
Ventricular Assist Device (HeartWare® VAS)
Device: HeartWare® VAS
The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Must be at least 18 years of age at enrollment.
  2. Body Surface Area (BSA) greater than or equal to 1.2 m2.
  3. Patient is NYHA Class IV
  4. Patient listed for cardiac transplantation
  5. Patient meets United Network for Organ Sharing (UNOS) Status 1A or 1B listing criteria.
  6. HeartWare® LVAD implant is planned as a bridge to transplant
  7. The patient or legally authorized representative has signed the informed consent form

Exclusion Criteria:

  1. Existence of any ongoing mechanical circulatory support (MCS) other than an intra-aortic balloon pump (IABP)
  2. Prior cardiac transplant.
  3. History of confirmed, untreated abdominal or thoracic aortic aneurysm > 5 cm.
  4. Cardiothoracic surgery within 30 days of enrollment.
  5. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave changes on the ECG, diagnostic biomarkers, ongoing pain and hemodynamic abnormalities as described (Figure 2) in the guidelines published in ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction; A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC Vol. 50, No.7, 2007.
  6. On ventilator support for > 72 hours within the fours days immediately prior to enrollment.
  7. Pulmonary embolus within three weeks of enrollment as documented by computed tomography (CT) scan or nuclear scan.
  8. Symptomatic cerebrovascular disease or a > 80% carotid stenosis.
  9. Patients have moderate to severe aortic insufficiency without plans for correction during pump implantation surgery.
  10. Patients with mechanical, animal or human tissue heart valves are excluded.
  11. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO)at the time of HeartWare® LVAD screening/enrollment or right atrial pressure > 20 mmHg on multiple inotropes, right ventricular ejection fraction (RVEF) <15% or clinical signs including lower extremity edema, ascites or pleural effusions refractory to treatment with diuretics and two inotropic drugs.
  12. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing, including but not limited to, continued positive cultures, elevated temperature and white blood cell (WBC) count, hypotension, tachycardia, generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment.
  13. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count < 100,000, INR > 1.6 or PTT > 2.5 times control in the absence of anticoagulation therapy).
  14. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
  15. Serum creatinine greater than 3.0 times the upper limit of normal within 48 hours of study enrollment or requiring dialysis (does not include use of ultra-filtration for fluid removal).
  16. All three listed liver enzymes [AST (SGOT), ALT (SGPT), or LDH] > 3 times upper limit of normal or a total bilirubin > 3 mg/dl within 24 hours of study enrollment, or biopsy proven liver cirrhosis or portal hypertension.
  17. Pulmonary vascular resistance is unresponsive (fixed) to pharmacologic manipulation as demonstrated by a pulmonary artery systolic pressure exceeding 60mmHg in conjunction with any one of the three following variables:

    • Pulmonary vascular resistance is greater than 5 Woods Units or
    • Pulmonary vascular resistance index is greater than 6 Woods Units or
    • Transpulmonary gradient exceeds 16 to 20 mmHg
  18. Patients requiring aortic, mitral, tricuspid or pulmonary valve replacements (including bioprosthetic valves) or left ventricular (LV) aneurysm resections.
  19. Participation in any other study involving investigational drugs or devices.
  20. Severe illness, other than heart disease, which would exclude cardiac transplantation.
  21. Pregnancy.
  22. Patient unwilling or unable to comply with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00751972

  Show 35 Study Locations
Sponsors and Collaborators
HeartWare, Inc.
Investigators
Principal Investigator: Mark Slaughter, MD Jewish Hospital/Univ of Louisville
Principal Investigator: Keith Aaronson, MD Univ of Michigan Medical Center
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: HeartWare, Inc.
ClinicalTrials.gov Identifier: NCT00751972     History of Changes
Other Study ID Numbers: HW003
Study First Received: September 10, 2008
Results First Received: March 15, 2013
Last Updated: April 2, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 18, 2014